https://scholars.lib.ntu.edu.tw/handle/123456789/634995
標題: | COVID-19: Updated Managements in Hospitalized Patients | 作者: | Tey, Shu Farn KUAN-YU CHEN SHIH-CHI KU |
公開日期: | 1-十二月-2022 | 卷: | 33 | 期: | 6 | 來源出版物: | Journal of Internal Medicine of Taiwan | 摘要: | At the end of 2019, a novel coronavirus was identified in cluster of pneumonia patients and spreading rapidly in Wuhan, China, resulting In a global pandemic In 2020. Taiwan had experienced two times of outbreak and peak since 2020. The Incidence and risk of critical illness of COVID-19 decreased gradually after most of the population has receivedthe administration of COVID-19 vaccine. Gradually easing of border restrictlonsand unlocking the restriction for COVID-19 was announced. After years of development, Nirmatrelvir + Ritonavir (Paxlovld), Molnuplravlr(Lagevrio) and NRICM101 are indicated for the patient who had the disease with mild severity and the risk factor of critical Illness. These treatments reduced the risk of disease progression and hospitalization rates. For the hospitalized patients, remdesivir is also indicated as alternative treatment for mild disease. For the patient who required oxygen supply and severe disease, combination treatment by dexamethasone with the Remdesivir, JAK Inhibitor (Barlcitinib), or lnterleukin-6 inhibitor (Tocilizumab) may improve survival and improve the recovery from the illness. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/634995 | ISSN: | 10167390 | DOI: | 10.6314/JIMT.202212_33(6).04 |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。